Latest News

 Stay up-to-date on the latest cancer research, fundraising news, and general news from Peter Mac. 

Discovery Partners are powering lifesaving research at Peter Mac. Meet the 2026 Fellows.
Expand
Research

2026 Discovery Partner Fellowships: supporting three promising clinical researchers

3 min read 07 October 2026

Three promising clinical researchers at Peter Mac have been awarded 2026 Discovery Partner Fellowships.

This year’s successful Fellows are Dr Emma Boehm, Dr James Buteau and Dr Liz Connolly.

The Discovery Partner Fellowships program is powered by Peter Mac Foundation’s generous regular donors, known as our Discovery Partners.

For ten years now, the Discovery Partner Fellowships program has provided essential funding to early or mid-career Peter Mac clinicians who also perform research.

The Fellowships provide financial support and allow researcher to carve out time from their clinical roles to pursue important research.

This initiative helps budding clinician-researchers with proven track records to build their research capacity and capability of clinicians. Further, it strengthens the breadth of research, enhances collaboration and enables lifesaving clinical research at Peter Mac.

Peter Mac Foundation Chief Executive Officer, Craig Connelly, said the Foundation was proud to deliver the Discovery Partner Fellowships through donor generosity.

"Every month, more than 60,000 Australians support our Discovery Partner program, and their generosity is helping turn promising ideas into research that has the potential to change lives," he said.

"Congratulations to this year's Fellowship recipients. We're proud to stand behind their work and look forward to seeing the difference their research will make for people affected by cancer."

Executive Director Cancer Research, Professor Ricky Johnstone, spoke to the vital role of the Fellowship program in helping clinician researchers build their research careers.

"For almost a decade, this program has provided talented clinician researchers with the opportunity to develop innovative research while continuing to deliver outstanding patient care. It's incredibly rewarding to see the impact our previous Fellows have gone on to make," he said.

"By providing protected research time, these Fellowships enable clinicians to accelerate projects that have the potential to improve cancer care, enhance the patient experience and shape the future of treatment.

"The calibre of applications this year was exceptional, highlighting the depth of talent across Peter Mac. We look forward to seeing the impact our researchers will have for patients and the broader cancer community."

This impact is all thanks to the support of Peter Mac’s wonderful Discovery Partner donors. Your kindness helps to accelerate breakthroughs in care for all people affected by cancer.

Here is the work your generosity is supporting in 2026:

Dr Liz Connolly
Advancing Translational Sarcoma Research and Proteomic Precision Oncology at Peter Mac

Sarcomas are a rare and diverse group of cancers with more than 80 subtypes that disproportionately affect children, adolescents and young adults. Their complexity makes them challenging to study and treat, and many patients still have limited treatment options.

The project will establish a collaborative sarcoma research program at Peter Mac, improving access to patient tissue samples and bringing together clinicians and researchers to advance sarcoma research. Using proteomics, the large-scale study of proteins, the program will identify which patients are most likely to benefit from emerging targeted therapies, including antibody-drug conjugates. These findings will be used to support the development of new clinical trials that match patients with treatments based on the unique biology of their cancer.

This research aims to bring precision medicine to more people with sarcoma, expand treatment options for this underserved cancer, and improve outcomes through more personalised and effective care.

Dr James Buteau
Accelerating Precision Oncology: Translating New Cancer Targets and AI-Enhanced Theranostics to the Clinic

Dr James Buteau’s project aims to develop new ways to find and treat cancer using theranostics – an approach that uses radioactive molecules to both detect cancer and deliver highly targeted treatment. Building on previous breakthroughs in prostate cancer, the project will explore whether this technology can be expanded to treat other cancers, including breast, ovarian and blood cancers.

The research has three main goals. First, it will test new cancer targets in people using advanced whole-body PET/CT imaging to understand where these molecules travel in the body and whether they can accurately find cancer. Second, it will launch the first clinical trials of a promising new radioactive treatment, terbium-161, to determine whether it is safe and effective for treating cancers beyond prostate cancer. Finally, the team will develop artificial intelligence tools to automatically analyse medical scans, helping doctors diagnose prostate cancer more accurately while reducing unnecessary biopsies.

Together, this work aims to improve cancer diagnosis, deliver more personalised treatments, and expand access to precision cancer care for patients with a wider range of cancers.

Dr Emma Boehm
Resolving diagnostic dilemmas in neuroendocrine tumours with molecular imaging and omics

Dr Emma Boehm’s research aims to improve the diagnosis and treatment of neuroendocrine tumours (NETs), a rare group of cancers that are often difficult to detect early. Because current tests can miss these cancers, many patients are diagnosed only after the disease has spread. The project will investigate whether advanced genetic testing and medical imaging can help identify NETs earlier and guide more personalised treatment.

The research will first evaluate whether whole genome sequencing can uncover important genetic changes that influence a patient's diagnosis, treatment options and family risk. The project will then examine how a tumour's genetic makeup affects what doctors see on PET scans, helping clinicians choose the most effective imaging tests and targeted radiation therapies. In the final phase, the team will develop better ways to diagnose insulin-producing pancreatic tumours (insulinomas), with the aim of replacing the current 72-hour fasting test with a faster, less invasive approach using advanced imaging, blood tests and artificial intelligence.

This research aims to make neuroendocrine tumours easier to diagnose, enable more personalised treatment, and improve outcomes for patients and their families.

Thank you to all our Discovery Partners who help make this research possible. Learn more about becoming a Discovery Partner.



Research is our best weapon against cancer

Make a tax-deductible donation and join the fight against cancer. 

Please review our  Privacy Policy for details about how we use and store your information.

@Follow us on Instagram (@SupportPeterMac)